Physician Resources

Guideline: Screening, assessment, and care of anxiety and depression in adults with cancer


 

References

A Canadian guideline on screening, assessment, and care of anxiety and depressive symptoms in adults with cancer has been adapted for the United States by the American Society of Clinical Oncology.

It is recommended that all patients with cancer be evaluated for symptoms of depression and anxiety at periodic times across the trajectory of care. Assessment should be performed using validated, published measures and procedures. Depending on levels of symptoms and supplementary information, differing treatment pathways are recommended. Failure to identify and treat anxiety and depression increases the risk for poor quality of life and potential disease-related morbidity and mortality, according to ASCO.

The full guideline can be found on the Agency for Healthcare Research and Quality website.

Recommended Reading

Aromatase inhibitors linked to dental problems
MDedge Hematology and Oncology
Impact of a telehealth intervention on quality of life and symptom distress in patients with head and neck cancer
MDedge Hematology and Oncology
Dying in America: implications for oncology of the recent IOM report
MDedge Hematology and Oncology
NIH report on long-term opioid treatment cites lack of data, research needs
MDedge Hematology and Oncology
David Henry's JCSO podcast, January 2015
MDedge Hematology and Oncology
FDA panel backs antifungal for invasive aspergillosis, mucormycosis
MDedge Hematology and Oncology
Commonly cited lymphedema risk factors ‘myth-busted’
MDedge Hematology and Oncology
Rise in reports of pain, depression in last year of life in oncology patients
MDedge Hematology and Oncology
Abuse-deterrent formulation of extended-release hydrocodone approved
MDedge Hematology and Oncology
Guideline: Therapy for women with HER2­-negative or unknown advanced breast cancer
MDedge Hematology and Oncology